Novartis AG
Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
Last updated:
Abstract:
The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
Status:
Grant
Type:
Utility
Filling date:
20 Oct 2017
Issue date:
14 Jun 2022